Key highlights
- MustGrow Biologics appointed Kevin Helash as CEO, effective Nov. 1, 2026
- Corey Giasson moved to Chief Operating Officer and Colin Bletsky to CCO
- MustGrow granted Helash 250,000 stock options, subject to TSX Venture Exchange acceptance
MustGrow Biologics Corp. (TSXV: MGRO) appointed Kevin Helash as chief executive officer, effective November 1, 2026, as the company updates its leadership team.
Helash has held CEO roles at Biotalys, Marrone Bio Innovations and Agrinos, and previously worked in senior executive roles at Agrium Inc. (now Nutrien). MustGrow’s chairman, Brad Munro, said Helash’s experience commercializing agricultural technologies and leading business transformations will help advance the company’s commercial priorities.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Leadership transition
MustGrow said Corey Giasson will transition to chief operating officer, with responsibilities including internal operations and production, as well as supporting ongoing development and commercialization activities. Colin Bletsky will transition to chief commercial officer, focusing on product sales and global market development, while also supporting development and commercialization activities.
Stock option grant
In connection with Helash’s appointment, MustGrow granted him 250,000 stock options under its Equity Incentive Plan. Each option entitles the holder to acquire one common share until November 1, 2033.
The options vest in tranches: 50,000 on November 1, 2026, and 50,000 on each of the first, second, third and fourth anniversaries of that date. The company said the grant remains subject to acceptance by the TSX Venture Exchange.
MustGrow describes itself as a provider of biological and regenerative agriculture solutions, with technology based on compounds found in mustard seed. The company said its flagship biofertility product, TerraSante, is registered, organically certified and commercially sold in parts of the United States, and that it is collaborating with Bayer AG in Europe, the Middle East and Africa to commercialize its products and technologies.
The original press release is available on stockhouse.com
s-5v2_h-6v2_i-7v2